References
- Williams AH, Gruneberg RN. Teicoplanin. J Antimicrob Chemother 1984; 14: 441–5.
- Fietta A, Bersani C, Mangiarotti P. In vitro activity of teicomycin against isolates of Gram-positive bacteria. Chemotherapy 1983; 29: 275–282.
- Peters G, Pulverer G. Antibacterial activity of teicomycin, a new glycopeptide antibiotic, in comparison to vancomycin. J Antimicrob Chemother 1983; 11: 94–5.
- Cynamon MH, Granato PA. Comparison of the in vitro activities of teicomycin A2 and vancomycin against staphylococci and enterococci. Antimicrob Agents Chemother 1982; 21: 504–505.
- Lewis P, Garaud JJ, Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by gram positive bacteria. J Antimicrob Chemother 1988; 21 (suppl A): 61–67.
- Bibler MR, Frame PT, Hagler DN, et al. Clinical efficacy pharmacokinetics, and safety of teicoplanin for serious gram positive infections. Antimicrob Agents Chemother 1987; 31: 207–212.
- Williams AH, Gruneberg RN, Webster A, et al. Teicoplanin in the treatment of infection caused by Gram-positive organisms. J Hosp Infect 1986; 7 (Suppl A): 101–103.
- Lang E, Schafer V, Schaff B, Dennhardt R. Comparison of efficacy and safety of teicoplanin in Gram-positive infections: a multicentre study. Scand Infect Dis 1990; 72: 54–60.
- Lefrok J, Smith B, Ristuccia P. Clinical evaluation of teicoplanin in skin, soft tissue and joint infections (abstract). In Proceedings of the 4th European Congress of Clinical Microbiology and Infectious Disease. Nice, France, No 966/pp43, 1989.
- Leport C, Perronne C, Massip P, et al. Evaluation of teicoplanin for treatment of endocarditis caused by Gram-positive cocci in 20 patients. Antimicrob Agents Chemother. 1989; 33(6): 871–876.
- Webster A, Wilson APR, Williams AH, et al. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis. Postgrad Med J 1987; 63: 621–624.
- Greenberg RN. Treatment of bone, joint and vascular access associated Gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990; 34: 2392–2397.
- Taylor RB, Reid RG, Gould IM. Determination of teicoplanin in plasma using microbore high-performance chromatography and injection generated gradients. J Chromatogr 1991; 563: 451–457.
- Bennett JV, Brachman PS. Hospital Infections. 2nd ed. Boston, Little and Brown, 1986.
- Mentar S. Gram-positive infection in the immunocompromised host. The Gram-positive Challenge, Medicine International. Supplement: 7–10, 1990.
- Gould IM. Prevention of infective endocarditis. Br Dent J 1988; 164: 31–2.
- Gorbach SL. Anaerobic cocci. In: Mandell GL, Douglas RG, Bennett JE (ed). Principles and Practice of Infectious Diseases. John Wiley & Sons, Inc. 1985; 205: 1373–1375.
- Brown NJ, Dinnaford PA, Perek D. Infectious complications of intraventricular reservoires in cancer patients. Paed Infect Dis 1987; 6: 182–9.
- Von Reyn CF, Levy BS, Arbeit RD, Frienland G, Crumpacker CS. Infective endocarditis: an analysis based on strict case definition criteria. Ann Int Med 1988; 94: 505–18.
- Braimbridge MV, Eykyn SJ. Prosthetic valve endocarditis. Antimicrob Chemother 1987; 20 (Suppl A): 173–80.
- Davey PG, Williams AH. Efficacy of teicoplanin alone and in combination in 15 cases of prosthetic valve endocarditis due to streptococci or staphylococci and eight cases of native valve endocarditis due to coagulase-negative staphylo cocci: Royal Society of Medicine Services International Congress and Symposium Series 1989; No 151: 137–143.
- Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with teicoplanin at 6 mg/kg/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother. 1991; 35: 79–87.
- Masur H, Johnson WD. Prosthetic valve endocarditis. J Thorac Cardiovasc Surg 1980; 80: 31–7.
- Waldvogel F, Calain P. Clinical efficacy of teicoplanin. Eur J Microbiol Infect Dis 1990: 9: 127–129.